Abstract
A novel porous polymeric (PPN) was engineered by integrating Dabrafenib, Enrofloxacin, Dipicolinic acid, Oxidized Pectin, and copper (Cu-DEOD PPN), resulting in a porous polymeric architecture with enhanced bioactivity. The synergistic combination of therapeutic and antimicrobial agents within a stable, biocompatible matrix endowed the nanocomposite with multifunctional properties, including anticancer, antibacterial, antioxidant, and analgesic effects. Structural characterization confirmed uniform dispersion of active constituents and a well-defined porous network. Key findings demonstrated an average particle size of 90 nm, and biological evaluation demonstrated significant efficacy: minimum inhibitory concentration (MIC) 2-8 µg mL(-1), minimum bactericidal concentration (MBC) 4-16 µg mL(-1), and half-maximal inhibitory concentration (IC(50)) 165 µg mL(-1) against NCI-H1299, and and up to 86% DPPH radical inhibition. The multifunctional performance of Cu-DEOD PPN highlights its potential as a versatile therapeutic platform for oncology, infection management, oxidative stress mitigation, and pain relief, providing a framework for the design of next-generation bioactive nanomaterials. This study emphasizes a strategic approach to developing multifunctional nanocomposites that simultaneously combine therapeutic potency, biocompatibility, and structural integrity, offering promising applications in pharmaceutical and biomedical research.